Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28803702 | 0.97 | DGAT1 (0.54) | DGAT1TSHRELANEALDH1A1KCNN4 | |
| Hydrochloric Acid SCHEMBL10829675 | 0.97 | DGAT1 (0.54) | DGAT1TSHRELANEALDH1A1KCNN4 | |
| SCHEMBL30440750 | 0.97 | DGAT1 (0.54) | DGAT1TSHRELANEALDH1A1KCNN4 | |
| SCHEMBL808799 | 0.84 | DGAT1 (0.74) | DGAT1TSHRELANEALDH1A1KCNN4 | |
| SCHEMBL23091415 | 0.81 | DGAT1 (0.70) | DGAT1TSHRELANEALDH1A1KCNN4 | |
| Ammonia Solution, Strong SCHEMBL7639328 | 0.81 | DGAT1 (0.70) | DGAT1TSHRELANEALDH1A1KCNN4 | |
| Iodide SCHEMBL10533676 | 0.81 | DGAT1 (0.70) | DGAT1TSHRELANEALDH1A1KCNN4 | |
| SCHEMBL27905901 | 0.81 | DGAT1 (0.70) | DGAT1TSHRELANEALDH1A1KCNN4 | |
| SCHEMBL5859056 | 0.79 | DGAT1 (0.59) | DGAT1TSHRELANEALDH1A1KCNN4 | |
| SCHEMBL9067049 | 0.79 | TSHR (0.42) | DGAT1TSHRELANEALDH1A1KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605622-A | Aliphatic polyester with malonic acid structure and preparation method and application thereof | 苏州瀚海新材料有限公司 | 2022-06-10 | — | — | CN | claimed |
| EP-0674233-B1 | Recording sheets | XEROX CORP (US) | 2000-05-24 | — | — | EP | claimed |
| US-5928765-A | Recording sheets | XEROX CORPORATION (US) | 1999-07-27 | — | — | US | claimed |
| EP-0674233-A2 | Recording sheets | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| US-20250067907-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250064789-A1 | KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | WESTVAC BIOPHARMA CO., LTD. (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4488264-A1 | KETO AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | WestVac Biopharma Co., Ltd. (CN) | 2025-01-08 | — | — | EP | disclosed |
| US-12139462-B2 | Pyridinone MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-116693447-B | Ketone amide derivative and pharmaceutical application thereof | 成都威斯克生物医药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4397366-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4367099-A1 | PYRIDINONE MK2 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-112601735-B | Compound, colored resin composition, color filter and display device | 东友精细化工有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-0066884-A2 | Oxygen-adsorbing and desorbing agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1982-12-15 | — | — | EP | disclosed |
| US-4327189-A | USING AN ENDCAPPED ACETAL RESIN HAVING STABILITY AGAINST DEPOLYMERIZATION | MONSANTO COMPANY (US) | 1982-04-27 | — | — | US | disclosed |
| EP-0049589-A1 | Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines | E.R. Squibb & Sons, Inc. (US) | 1982-04-14 | — | — | EP | disclosed |
| US-4311705-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-19 | — | — | US | disclosed |
| US-4303777-A | DEFLOCCULATION AGENT | MONSANTO COMPANY (US) | 1981-12-01 | — | — | US | disclosed |
| US-4302564-A | ADDING AN ELECTRONEGATIVE END GROUP TO AN ACETAL RESIN OF AN ESTER OF GLYOXYLIC ACID | MONSANTO COMPANY (US) | 1981-11-24 | — | — | US | disclosed |
| US-4238506-A | SECONDARY OR TERTIARY AMIDE-SUBSTITUTED | BOEHRINGER MANNHEIM GMBH (DE) | 1980-12-09 | — | — | US | disclosed |
| US-4113871-A | HYPOGLYCEMICALLY AND HYPOLIPIDEMICALLY ACTIVE DERIVATIVES OF PHENYL-ALKANE-CARBOXYLIC ACIDS | BOEHRINGER MANNHEIM GMBH (DE) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139462-B2 | Pyridinone MK2 inhibitors and uses thereof | ENPP2, PLP2, PDXK | DGAT1 3136/4885TSHR 3826/4885ELANE 3566/4885 |
| US-20250067907-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | DGAT1 4553/4885TSHR 667/4885ELANE 1892/4885 |
| US-20250064789-A1 | KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ACE2, ACE, PKD2 | DGAT1 257/4885TSHR 3558/4885ELANE 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.